The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Tyler Van Buren - Cowen and Company LLC - Analyst
: Congratulations on tremendous results in asthma here. Regarding the ASPIRE trial that you're planning for, I don't believe you guys said
whether it would be Phase 2 or Phase 3. So considering the fact that the AD Phase 2 program is exploring dose ranging and that you guys
like to run fast in development. Is it possible that the ASPIRE trial could be a pivotal trial in asthma?
LSEG STREETEVENTS | www.lseg.com | Contact Us
consent of LSEG. 'LSEG' and the LSEG logo are registered trademarks of LSEG and its affiliated companies.
JANUARY 06, 2026 / 1:00PM, APGE.OQ - Apogee Therapeutics Inc to Discuss APG777 Asthma Phase 1b
Interim Results
Question: Julian Harrison - BTIG LLC - Analyst
: Congratulations on the data. Keeping in mind patients in the study only received a single dose of Zumi, do you have any thoughts or
expectations with regards to deepening responses following multiple doses in future studies? And then I think I know the answer to this
LSEG STREETEVENTS | www.lseg.com | Contact Us
consent of LSEG. 'LSEG' and the LSEG logo are registered trademarks of LSEG and its affiliated companies.
JANUARY 06, 2026 / 1:00PM, APGE.OQ - Apogee Therapeutics Inc to Discuss APG777 Asthma Phase 1b
Interim Results
next question, but just to clarify, do you necessarily have to have the best in category biologic in asthma for commercial success here? Or
Question: David Nierengarten - Wedbush Securities Inc - Analyst
: I just had one for Dr. Castro. I know the off-label use, but if you have treated patients who maybe have been -- who fit the profile of the
patient who would benefit from IL-13 if you've treated any of your patients with Epic if the results were consistent with the [post-loanalysis]
from the previous studies.
Question: David Nierengarten - Wedbush Securities Inc - Analyst
: Yes, treating the patients you might expect would benefit the hit in the bills or other markers.
Question: David Nierengarten - Wedbush Securities Inc - Analyst
: Yes, using (inaudible) IL-13.
Question: David Hoang - Deutsche Bank AG - Analyst
: So I think you -- I believe you mentioned with the APG808 molecule, your IL-4 RA, you had looked at that and you saw a bounce back in
FeNO at 8 weeks. And here, obviously, the durability is going out to 16 weeks plus with IL-13. Could you just comment on if that is sort of in
line with your expectations around the kind of the biology here. And the durability with the IL-13 additional durability? What is driving that
versus the less with the 808 molecule.
Question: Joseph Catanzaro - Mizuho Securities USA LLC - Analyst
: Appreciate the update. Maybe one from me, somewhat related to the PK/PD relationship. I'm wondering if the durability of FeNO reduction
is out to 32 weeks, aligns with exposures at that time point that you would expect to be efficacious? And if so, how much beyond week 32,
do you expect exposures to remain above that efficacious level?
| 
